Shared on05 Oct 25
Fair value Increased 1.61%

Analysts have lowered their price targets for Baxter International to $25 from previous levels above $36, citing concerns about slower than expected margin expansion, delayed sales growth recovery, and business challenges highlighted in recent guidance cuts. Analyst Commentary Recent analyst reports have provided a mixed outlook for Baxter International, highlighting both challenges and potential positives as the company navigates through a period of transition and recovery.

Shared on05 Sep 25
Fair value Decreased 1.22%

Baxter International's consensus price target was slightly reduced to $29.00, as disappointing Q2 results, lowered full-year guidance, and a slower-than-expected path to sales and margin improvement undermined near-term growth confidence. Analyst Commentary Disappointing Q2 performance and reduced full-year guidance undermined near-term confidence in Baxter's growth trajectory.

Shared on04 Aug 25
Fair value Decreased 21%

Baxter International’s consensus analyst price target has been significantly reduced, primarily driven by downward revisions in both revenue growth forecasts (from 5.2% to 3.7% per annum) and net profit margin (from 7.71% to 7.02%), resulting in a new fair value estimate of $29.89. What's in the News Baxter provided Q3 and full-year 2025 sales guidance, projecting 6–7% reported sales growth from continuing operations and 3–4% operational growth.